The NADK antibody is a crucial tool in studying nicotinamide adenine dinucleotide kinase (NADK), an enzyme responsible for catalyzing the phosphorylation of NAD⁺ to generate NADP⁺. This reaction is essential for maintaining cellular redox balance and providing NADPH, a critical cofactor in biosynthetic processes and antioxidant defense. NADK is localized in the cytoplasm and mitochondria, with its activity influencing metabolic pathways such as lipid synthesis, glutathione regeneration, and oxidative stress response. Researchers use NADK antibodies to detect and quantify NADK expression in various biological samples, aiding investigations into metabolic disorders, cancer, and neurodegenerative diseases where NADK dysregulation is implicated. These antibodies are validated for applications like Western blotting, immunohistochemistry, and immunofluorescence, often demonstrating specificity for human, mouse, or rat NADK isoforms. Both monoclonal and polyclonal NADK antibodies are available, with monoclonal variants offering higher specificity and reproducibility. Recent studies highlight NADK's role in cancer cell proliferation and chemoresistance, making its antibody a valuable asset in exploring therapeutic targets. Quality control measures, such as knockout validation and cross-reactivity testing, ensure antibody reliability in experimental models.